Find financial news and analysis across NZ and Australia.
2 results for “cxbladder”
Pacific Edge Limited has initiated a trading halt to conduct a NZ$24 million capital raise aimed at regaining US Medicare coverage. The company reported a significant revenue drop to NZ$11.5 million in FY26 following the loss of reimbursement for its Cxbladder tests.
Pacific Edge Limited has successfully raised NZ$25.4 million through an upsized placement to fund its Cxbladder operations and efforts to regain US Medicare coverage. The company will now launch a NZ$6 million retail offer to existing shareholders.